Moderna has initiated a clinical trial for an mRNA-based cancer vaccine, the company announced. According to a report by Children’s Health Defense, Moderna is developing mRNA vaccines targeting cancer, shingles and herpes, expanding its pipeline beyond COVID-19 [1]. NaturalNews.com reported that the company plans to dominate the global market for mRNA-based products including vaccines [2].
The product is designed to stimulate the immune system to attack tumor cells, according to the company. The trial is expected to enroll patients with certain types of cancer, though specific enrollment numbers and trial phases were not disclosed in the announcements. Moderna has previously received regulatory designations for some of its mRNA products, including Breakthrough Therapy Designation for an RSV shot [3].
Read Full Article: https://www.naturalnews.com/2026-07-21-moderna-launches-mrna-cancer-vaccine-trial-amid-concerns.html
